AI’s Legal Challenge – Jury to Unravel Thomson Reuters and Ross Intelligence Dispute
Thomson Reuters Corp (NYSE: TRI) will face Ross Intelligence in court, as a Delaware federal judge ruled that a jury should decide the lawsuit's outcome.
Ernst & Young’s Ambitious AI Agenda: $1.4B Investment, EY.ai EYQ, and Workforce Training
Consulting firm Ernst & Young disclosed a significant investment of $1.4 billion into artificial intelligence and the introduction of its proprietary large language model, EY.ai EYQ. EY also unveiled plans to provide AI training to its extensive workforce comprising 400,000 employees.
AI’s Growing Influence: Over 7,000 Mentions In Q2 Earnings Calls Boost Stocks
There’s no doubt that artificial intelligence is earning a spot in the list of groundbreaking technological revolutions, quickly…
Expect ‘Limited Reaction From China’ To Biden’s Quantum, Semiconductor Investment Order, Analyst Says
On Wednesday, President Joe Biden signed an executive order restricting certain U.S. investments in China’s key technology sectors.…
US Credit Rating Cut Triggers Surge In Treasury Yields: 7 ETFs Experience Wild Swings
U.S. Treasury yields experienced a significant surge on Wednesday, influenced by a combination of factors including elevated issuance…
Top Investment Bank Unveils 3 ETFs, 10 Stocks To Buy In The AI Boom
Analysts at Bank of America say that artificial intelligence (AI) has the potential to unleash extraordinary productivity growth,…
The US Is Trying To Weaken China’s Semiconductor Industry: Here’s What China Is Doing To Fight Back In AI Race
In a bid to stymie China’s accelerating technological advancements, the U.S. government is considering stringent export restrictions on…
NVIDIA, Chipmakers Brace For Impact As US Mulls New Chip Export Restrictions To China: Could This End AI Stock Rally?
The U.S. government is contemplating new restrictions on the export of AI chips to China in an effort…
AI in Medical Field: Hong Kong Company Takes First AI-Generated Drug Candidate To Clinic Targeting Chronic Lung Disease
Insilico Medicine, a biotechnology company based in Hong Kong, has initiated a 12-week Phase 2 clinical trial for the first-ever drug created by artificial intelligence, INS018_055 targeting idiopathic pulmonary fibrosis (IPF), a type of chronic lung disease.
